Heterologous prime-boost immunization combining parenteral and mucosal routes with different adjuvants mounts long-lived CD4+ T cell responses in lungs
These results suggest that an immunization regimen consists of parenteral priming with H56+CAF01 followed by an airway boosting with H56 protein and mucosal adjuvants holds promise in mounting combined systemic and mucosal immune responses to <i>Mycobacterium tuberculosis</i>, and as such warrants further exploration. Given the rising interest in mucosal vaccines for respiratory pathogens, these findings offer an important immunological framework for future translational studies.
Authors
- Manuela Terrinoni (ORCID: https://orcid.org/0000-0002-2664-3210)
- Dennis Christensen (ORCID: https://orcid.org/0000-0003-2382-8639)
- Ali M. Harandi
- Siggeir F. Brynjólfsson (ORCID: https://orcid.org/0000-0003-0451-5581)
- Thorunn A. Olafsdottir (ORCID: https://orcid.org/0000-0001-5454-938X)
- Ranmali Kavishna (ORCID: https://orcid.org/0000-0002-0066-8727)
- Tobias Gustafsson‐Hedberg (ORCID: https://orcid.org/0000-0001-7179-6710)
- Jan Holmgren (ORCID: https://orcid.org/0000-0003-1784-5918)
- Peter Andersen (ORCID: https://orcid.org/0000-0002-5869-2551)
Institutions
- Statens Serum Institut (DK)
- University of Gothenburg (SE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-07-01
- DOI
- https://doi.org/10.3389/fimmu.2025.1599713
- Citations
- 1
- Primary Topic
- Tuberculosis Research and Epidemiology
- Type
- article
- Field-Weighted Citation Impact
- 1.40
Funders
- European Commission